China
Africa
Explore chapters and articles related to this topic
Health System Pharmacy
Published in William N. Kelly, Pharmacy, 2018
340 B Drugs—The 340B Drug Pricing Program allows certain hospitals and other healthcare providers (“covered entities”) to obtain discounted prices on “covered outpatient drugs” (from drug manufacturers). Manufacturers must offer substantial 340B discounts to covered entities to have their drugs covered under Medicaid.
Building the foundation for a community-generated national research blueprint for inherited bleeding disorders: facilitating research through infrastructure, workforce, resources and funding
Published in Expert Review of Hematology, 2023
Margaret V. Ragni, Guy Young, Glaivy Batsuli, Emily Bisson, Shannon L. Carpenter, Stacy E. Croteau, Adam Cuker, Randall G. Curtis, Michael Denne, Bruce Ewenstein, Amber Federizo, Neil Frick, Kerry Funkhouser, Lindsey A. George, W. Keith Hoots, Shawn M. Jobe, Emily Krava, Christopher James Langmead, Roger J. Lewis, José López, Lynn Malec, Ziva Mann, Moses E. Miles, Emma Neely, Ellis J. Neufeld, Glenn F. Pierce, Steven W. Pipe, Lisa R. Pitler, Leslie Raffini, Kathaleen M. Schnur, Jordan A. Shavit
The majority of the remaining top tier priority initiatives concern funding, are expected to have a high impact at low cost, and to be relatively easy to implement in the short term. These include knowledge sharing to empower all centers to optimize their capacity to invest revenue from the 340B Drug Pricing Program [9] back into clinical care and research to enhance patient care. The subgroup identified several federal and government agency, foundation, philanthropic, society, and industry resources, not limited to the hematology sphere, that should be expanded to include all multidisciplinary team professionals (not just clinicians) at all career stages (Suppl Table S3). A single website consolidating information on all opportunities would be enormously helpful in facilitating maximum capitalization on these opportunities. Hematology professional organizations should embrace inclusivity with membership reflective of all the professions that contribute to comprehensive care. The subgroup also identified the importance of raising the profile of hematology, both publicly and among HCPs potentially making career direction choices, for example through inclusion as a category in the U.S. News & World Report evaluation of hospitals [50], which they propose may be achieved through lobbying.
Building the foundation for a community-generated national research blueprint for inherited bleeding disorders: research priorities in health services; diversity, equity, and inclusion; and implementation science
Published in Expert Review of Hematology, 2023
Vanessa R. Byams, Judith R. Baker, Cindy Bailey, Nathan T. Connell, Melissa S. Creary, Randall G. Curtis, Alexis Dinno, Christine J. Guelcher, Michelle Kim, Roshni Kulkarni, Susan Lattimore, Keri L. Norris, Lucy Ramirez, Mark W. Skinner, Susan Symington, Patricia Tobase, Esmeralda Vázquez, Beth B. Warren, Emily Wheat, Tyler W. Buckner
While PWIBD receiving care at HTCs generally report a high level of satisfaction [31–33], their numbers are increasing [19,34] and the treatment landscape complexity is intensifying [35,36]. HSR examines access to high quality, affordable care, health inequities, and individuals who may encounter more barriers [20,32,37]. Most HTCs rely on revenue generated through the HRSA US 340B Drug Pricing Program to finance essential staff and services [20,38]. Sustainable funding of the HTC model in the changing treatment paradigm and financial barriers encountered by PWIBD related to high treatment costs, insurance coverage, copay assistance program issues, and out-of-pocket costs constitute important current and imminent challenges that could be better understood through HSR [19,20,34,39].
Role of ethnicity/language in documented rates of pediatric asthma prescription refills
Published in Journal of Asthma, 2023
Jennifer A. Lucas, Jorge Kaufmann, Matthew Jones, Arvin Garg, David Ezekiel-Herrera, Jon Puro, Miguel Marino, John Heintzman
Asthma, for many children, is managed by primary care providers (10). National Asthma Education and Prevention Program’s Expert Panel Report states that one of the main goals in asthma care is asthma control, which includes reducing impairment, and reducing risk (e.g. preventing exacerbations and decreasing emergency care) (1). CHCs are an ideal setting to examine asthma medication prescription in Latino children. A disproportionately large portion of low-income, Latino children in the US receive some or all of their care from primary care providers at CHCs, which receive federal funding to provide care to all who need it regardless of ability to pay for care (11,12). CHCs are also eligible for reduced drug pricing under the 340B Drug Pricing Program, savings which can be passed on to patients (13,14).